The new joint venture, DolCas-Tenshi Bioceuticals Inc., is targeting male sexual health in its debut nutraceutical formula, marketed under the name Fortiquin™. This five-ingredient, patent-pending blend of herbal extracts and nutrients has been carefully designed to support sexual stamina and overall wellbeing in healthy men experiencing problems with sexual performance. The company will launch the all-natural, vegan complex at Vitafoods Europe in Geneva on May 7-9, 2018, booth #F200.

Derived from the wisdom of the Ayurvedic medical tradition, Fortiquin is composed of four botanicals: mucuna, cynara, trigonella and ashwanghanda, combined with the amino acid L-arginine. The proprietary blend of natural ingredients works in synergy to nourish and balance multiple systems for the overall enhancement of men’s health and, more specifically, sexual stamina. Comprehensive clinical studies are ongoing.

The symbiotic blend of extracts, in proprietary ratios, are standardized to their bioflavonoid and saponin contents. These two classes of phytochemicals are commonly touted for their therapeutic activity, including their effects on the reproductive, vascular and nervous systems.

The supplement market for sexual performance aids is projected to grow exponentially into 2021. Technavio Research forecasts a steady annual growth rate of about 12% over the 5 year period, with a projected market value of about $376 million.
Several factors are driving the expansion of this dynamic niche market. Evolvement of societal perceptions and norms regarding sexual intimacy is eliciting increased customer acceptance of sexual enhancement supplements. Additionally, the anonymity and convenience of internet shopping appears to encourage increased e-commerce activity within this sector.

The potential for Fortiquin is vast. The release of the publication proving its clinical effects on sexual function in men is expected in the late spring of this year. The uniqueness of Fortiquin’s composition potentially avails it to other clinical functions, such as sports performance and menopausal support. Dolcas-Tenshi plans to further investigate Fortiquin’s applicability for these additional health areas.

www.dtbioceuticals.com